Paper: Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States
Program: Oral and Poster Abstracts Type: Oral Session: 904. Outcomes Research – Non-Malignant Conditions: What to Know: Management Costs and Outcomes in Various Non-Malignant Disorders Hematology Disease Topics & Pathways: Sickle Cell Disease, Clinical Practice (Health Services and Quality), Hemoglobinopathies, Diversity, Equity, and Inclusion (DEI) , Diseases George Goshua, MD, MSc 1, Satoko Ito, MD PhD 1, Karthik Chetlapalli, MS, BS 2, Kunal C Potnis, MD 3 *, Cecelia Calhoun, MD, MBA, MPH 1, Lakshmanan